Key facts
- Notable investors include Zheshang Venture Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Zhisheng Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Zhisheng Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zhisheng Bio
Provider and developer of innovative drugs intended to treat refractory wounds. The company focuses on fibroblast growth factor drugs and targets diabetic foot and skin ulcers for pets, enabling patients with better treatment for refractory wounds.
- Sector
- Healthcare
- HQ
- China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Zhisheng Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zhisheng Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zhisheng Bio in its N-PORT filings yet. We sweep new filings monthly.